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ABSTRACT
Background: Constant flow and concentration CO2
has previously been efficacious in attenuating
ventilatory oscillations in periodic breathing (PB) where
oscillations in CO2 drive ventilatory oscillations.
However, it has the undesirable effect of increasing
end-tidal CO2, and ventilation. We tested, in a model of
PB, a dynamic CO2 therapy that aims to attenuate
pacemaker-induced ventilatory oscillations while
minimising CO2 dose.
Methods: First, pacemakers were manipulated in 12
pacemaker recipients, 6 with heart failure (ejection
fraction (EF)=23.7±7.3%) and 6 without heart failure,
to experimentally induce PB. Second, we applied a
real-time algorithm of pre-emptive dynamic exogenous
CO2 administration, and tested different timings.
Results: We found that cardiac output alternation
using pacemakers successfully induced PB.
Dynamic CO2 therapy, when delivered coincident
with hyperventilation, attenuated 57% of the
experimentally induced oscillations in end-tidal CO2:
SD/mean 0.06±0.01 untreated versus 0.04±0.01 with
treatment (p<0.0001) and 0.02±0.01 in baseline non-
modified breathing. This translated to a 56% reduction
in induced ventilatory oscillations: SD/mean 0.19±0.09
untreated versus 0.14±0.06 with treatment (p=0.001)
and 0.10±0.03 at baseline. Of note, end-tidal CO2 did
not significantly rise when dynamic CO2 was applied
to the model (4.84±0.47 vs 4.91± 0.45 kPa,
p=0.08). Furthermore, mean ventilation was also
not significantly increased by dynamic CO2
compared with untreated (7.8±1.2 vs 8.4±1.2 L/min,
p=0.17).
Conclusions: Cardiac pacemaker manipulation can be
used to induce PB experimentally. In this induced PB,
delivering CO2 coincident with hyperventilation,
ventilatory oscillations can be substantially attenuated
without a significant increase in end-tidal CO2 or
ventilation. Dynamic CO2 administration might be
developed into a clinical treatment for PB.
Trial Registration number: ISRCTN29344450.
INTRODUCTION
Periodic breathing (PB) is a waxing–waning
ventilatory pattern, typically with a cycle
length of 60 s, generated by oscillations in
respiratory gases1 via an enhanced and
delayed chemoreﬂex response.2–4 Common
in heart failure (HF),5 6 PB is associated with
sleep disruption, adrenergic overactivation
and increased mortality.7 8
Whether the physiological oscillations of
PB contribute to the increased mortality is
unknown, but it is plausible that by disrupt-
ing sleep they contribute to the fatigue that
is characteristic of HF even in patients whose
cardiac output at rest is not so low that
fatigue would be expected.
A variety of techniques such as adaptive
servoventilation (ASV) have been reported to
improve sleep disordered breathing, left
KEY MESSAGES
What is already known about this subject?
▸ Current treatments for central sleep apnoea,
which may affect up to 50% of heart failure
patients, have been marred by poor compliance
possibly due to the fact that they obligate the
use of tight fitting masks.
What does this study add?
▸ This study trials small doses of carefully-timed
carbon dioxide which is delivered for short dura-
tions within each ventilatory cycle in a novel
pacemaker model of periodic breathing.
How might this impact on clinical practice?
▸ It is hoped that this could be applied therapeut-
ically for central sleep apneoa with a delivery
system such as nasal cannulae which would
avoid the use of tight-fitting masks.
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ventricular ejection fraction, exercise capacity and
quality of life.9 10 Although long-term data are lacking,
large randomised controlled trials are currently being
conducted. Continuous positive airways pressure, an
earlier and simpler technology, is uncomfortable for
many patients. Its only large scale trial was unable to
recruit more than two-thirds of the planned sample size
and a further one-sixth of randomised patients withdrew
from the trial; those remaining in the trial were using
the therapy for less than 4 h per night after the ﬁrst
year. The trial did not show any mortality effect.11
Eliminating the requirement for tight ﬁtting masks
would permit a greater range of patients to ﬁnd the
therapy acceptable and might permit them to use it for
longer during the night without discomfort. The key to
eliminating the requirement for a tight-ﬁt might be to
not manipulate ventilation directly but rather use the
patient’s own chemoreﬂex to allow an intervention to be
delivered in the form of CO2 and be translated into ven-
tilation by the patient’s own biology.
Prior attempts to use CO2 to alleviate PB have employed
continuous, constant doses of exogenous CO2 throughout
the PB cycle (‘static’ CO2 therapy), sometimes via the add-
ition of dead-space, in order to raise the mean arterial CO2
level above the apnoeic threshold. While effective in redu-
cing apnoeas, high doses of exogenous CO2 have the
undesirable effects of potentiating the sympathetic nervous
system and elevating mean ventilation.12–14 This is particu-
larly hazardous in HF where the supply–demand balance is
precarious and further increases in metabolic demand may
be compromising. Static CO2 therapy, therefore, has not
been implemented in routine clinical practice.
Previous work by our group suggests it may be possible
to speciﬁcally target troughs in end-tidal CO2 using
low-dose, carefully timed, brief administrations of CO2.
This is analogous in many ways to ASV with therapy
aimed at the current ventilatory instability. In dynamic
CO2 administration, the aim is to attenuate or eliminate
the troughs in CO2 that result from an enhanced che-
moreﬂex gain and the hyperventilation phase of PB. In
doing so, despite the intrinsic reﬂex being unchanged
by the therapy, we aim to prevent the exaggerated
response to what would have been the hypocapnia
phase, namely the apnoea or hypopnoea that would
then themselves have triggered a disproportionate rise
in CO2. Wrongly timed ‘dynamic’ therapy, therefore,
even with very small doses of CO2, has the potential to
exacerbate ventilatory oscillations. Therefore, a system
that allows prediction of the timing and size of troughs
in end-tidal CO2 has been developed.
15 16
Repetitive alternation of cardiac output using cardiac
permanent pacemakers (PPMs) can engender oscilla-
tions in respiratory gases and ventilation, a process
which could be used to model PB, thereby facilitating
therapeutic algorithm development.16 17 The alternation
of cardiac output from high to low every 30 s produces
oscillations in ventilation with cycle length of 60 s that
are not unlike the oscillations of spontaneous PB.17
Unlike spontaneous PB seen in HF, in this model
there is a continuous exogenous driver to oscillation,
such that any improvement following intervention may
be conﬁdently attributed to the intervention, useful
because the severity of spontaneous PB is variable and
unpredictable.18 Moreover, this experimental model,
rather than models of voluntarily simulated PB, allows
monitoring of the effect on ventilation.19–22 The model
is not identical to spontaneous PB, whose cycle time and
amplitude are different between different patients and
can ﬂuctuate with time, although in our experiment the
therapy algorithm does not have prior knowledge of the
true cycle time or amplitude and has to deduce this
from the ventilatory patterns being observed in real
time. This goes some way to simulating the ultimate clin-
ical application environment while retaining the advan-
tages of experimental reproducibility of an underlying
PB pattern that is relatively consistent.
In this study, we applied pacemaker manipulation to
produce an experimental model of PB by alternating
cardiac output. We then aimed to deliver CO2 using our
pre-emptive CO2 delivery system. This required real-time
prediction of when CO2 was likely to fall, and then
exogenous CO2 to be delivered to ﬁll the troughs in
end-tidal CO2, thereby preventing the resultant hypoven-
tilation. We aimed to stabilise ventilation, while minimis-
ing the amount of CO2 administered and the
consequent undesirable increase in mean ventilation.
METHODS
Subjects
Of 21 patients screened, 3 were excluded for demon-
strating PB at baseline, 5 because of heart rates >80 bpm
at rest and 1 for signiﬁcant lung disease. Twelve patients
with PPM (4 with cardiac resynchronisation devices, 8
with dual or single chamber pacemakers; table 1) were
ﬁnally recruited from outpatient cardiac services
between 2007 and 2009. All implants were at least
3 months prior to recruitment. Six patients had echocar-
diographic (ejection fraction <50%), and clinical fea-
tures of HF and six had normal systolic function.
Exclusion criteria were implantable cardiac deﬁbrilla-
tors with antitachycardia therapy set at rates lower than
120 bpm, conditions precluding lying for 90 min, recent
decompensation, ventilatory disorders, end-stage renal
failure and medication affecting ventilatory drive. Within
patients with HF, there was no evidence of daytime PB
or exercise oscillatory ventilation but two patients
demonstrated cardiac cachexia. The six patients without
HF had pacemaker implantation for the following indi-
cations: atrioventricular (AV) node ablation, vasovagal
syncope, ﬁrst-degree heart block, sick sinus syndrome,
complete heart block and sinus bradycardia.
On the study day, patients were monitored for 30 min
while recumbent on a couch, in order to exclude spon-
taneous PB. All patients gave informed consent for the
study, which was approved by local research ethics
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committee (05/Q0404/018). The investigation con-
formed to the principles outlined in the Declaration of
Helsinki.
Measurements
Patients breathed through a calibrated pneumotacho-
graph attached to a Multicap monitor (Datex
Instumentarium, Helsinki, Finland) measuring ventila-
tion and respiratory gases. An electrocardiogram signal
was recorded using a Hewlett-Packard 78351A.
Beat-by-beat blood pressure and cardiac output were
measured non-invasively using a photoplethysmograph
device (Finometer, Finapres Medical Systems, The
Netherlands).23
Data acquisition
The data were sampled at 1000 Hz using a custom data
acquisition system consisting of an analogue-to-digital
card (DAQCard 6062E, National Instruments, Austin,
Texas, USA) and a workstation running software written
in Labview instrument control language (V.7.0, National
Instruments). This system allowed data to be collected
simultaneously from all the devices and later analysed
off-line using software written in Matlab (Natick,
Massachusetts, USA).16–18 Heart rate, blood pressure,
cardiac output, end-tidal gas concentrations and ventila-
tion were digitally interpolated and resampled to obtain
signals at 1 Hz for subsequent analysis.13 14
Pacemaker protocol
Pacemaker reprogramming was performed via a pace-
maker telemetry head positioned over the implanted
pacemaker device. In all patients, the maximum possible
safe change in cardiac output was elicited by changing
heart rate, AV delay and pacing conﬁguration where pos-
sible (eg, from right ventricular pacing to biventricular
pacing). On average, the heart rate was changed from
59.5±10.2 to 79.1±10.7 bpm (p<0.01). Cardiorespiratory
variables were monitored while alternating the cardiac
output as a step change, between low cardiac output
and high cardiac output, every 30 s for at least ﬁve cycles
of 60 s (untreated). Cardiac output was altered in
exactly the same way for exactly the same duration
during the dynamic CO2 therapy administrations.
CO2 administration system
Starting from a ﬁxed concentration of CO2 in a non-
pressurised reservoir, we delivered exogenous CO2 using
a specially designed motorised valve, in any desired con-
ﬁguration using custom software (Matlab, Natick,
Massachusetts, USA,13 14 16–18). This performed
real-time analysis of ventilation and, using Fourier trans-
formation, calculated the magnitude and the phase of
ventilatory oscillations within the cycle at 1 s intervals
during the experiment.
The motor drove a valve, which enabled the inspired
gas mixture composition to be varied continuously to
any desired value between atmospheric and the concen-
tration of the CO2 cylinder. The administration algo-
rithm was programmed to give CO2 doses dependent on
the magnitude and phase of the current oscillation
(ﬁgure 1).
The CO2 concentration was varied smoothly: it began
from zero concentration, then rose smoothly to the
peak of administration and then declined similarly to
ﬁnish at zero again (ﬁgure 2). The peak concentration
administered was automatically adjusted in real time to
be proportional to the amplitude of the ventilatory
oscillations, in order to prevent either over or under
treatment12 (ﬁgure 3). The dose required was recalcu-
lated every second based on the above principles and
was translated into an electrical output to the motor. In
the case of no ventilatory oscillations, no CO2 was deliv-
ered (ﬁgure 3).
CO2 administration protocol
During baseline cardiac output alternation (at least ﬁve
60 s cycles), no CO2 was administered. CO2 was then
delivered at a phase that allowed peak alveolar concen-
tration to be coincident with peak ventilation, for at least
ﬁve 60 s cycles. We aimed to set the timing of delivery at
the motor so that the peak concentration of inspired
CO2 would be arriving at the alveolar level at approxi-
mately the peak of ventilation. In each subject, the time
interval between motor movement and the increment in
end-tidal CO2 during baseline breathing was measured
and on average this was 9 s.
Table 1 Baseline characteristics
Heart
failure
Non-heart
failure
n 6 6
Age (years) 72.5±9.3 71.0±8.8
Male 5 3
Height (cm) 171.3±8.3 166.8±10.2
Weight (kg) 77.0±10.6 83.4±15.6
Ejection fraction (%) 23.7±7.3 54.3±7.2
Heart rate (bpm) 64±15 55±3
Cardiac output (L/min) 4.5±21 7.6±2.8
End-tidal CO2 (kPa) 4.6±0.7 5.1±0.2
Mean ventilation (L/min) 8.1±1.8 7.5±1.5
NYHA 2/3/4 2/3/1
Aetiology
Ischaemic 4
Dilatative 1
Valvular 1
Alcoholic 0
Treatment
Biventricular pacemaker 4
ACE inhibitor/ARBs 4
Beta-blockers 3
Aldosterone antagonists 4
Diuretics 2
ARBs, Angiotensin II Receptor Blockers; NYHA, New York Heart
Association.
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In between interventions there was a ‘washout period’
where cardiac output continued to be alternated but no
CO2 delivered. In a separate run, in order to assess the effect
of phase on ventilation, CO2 was delivered so that the CO2
would arrive coincident at the alveolar level with trough ven-
tilation, in antiphase to the initial therapeutic algorithm.
Figure 1 Top left: Each ventilatory cycle may be graphically represented as a clock with peak ventilation (a) at 12 o’clock,
mid-ventilation (b) at either 3 o’clock or 9 o’clock (depending on whether ventilation is decreasing or increasing) and trough
ventilation at 6 o’clock. Fourier analysis allows the amplitude (A) and cycle length (P) to be established. Low amplitude oscillations
(i) are represented as nearer to the centre of the clock than medium (ii) or large (iii) oscillations. At any time, the current position
within the PB cycle can, therefore, be appreciated by the position of the cursor. As ventilation stabilises the cursor moves closer
towards the centre of the clock face. Bottom right: CO2 was delivered from 0 to peak concentration gradually and then falling back
to 0 with a ‘1-cos’ profile for a fraction of the PB cycle. Here dynamic CO2 is being delivered coincident with peak ventilation. Both
the duration and peak dose of CO2 delivered are proportional to the size of the oscillations so the smaller oscillations receive a
lower peak CO2 concentration for a shorter period of time (smallest sinusoidal administration) and the largest ventilatory oscillations
receive both a longer administration and a higher peak CO2 concentration (largest sinusoidal profile).
Figure 2 Schematic of
laboratory set-up. CO2 and air are
allowed to mix to any desired
concentration using a
computer-controlled motorised
valve. This mixture is drawn in by
the patient on inspiration and
expired via a three-way valve.
Inspired and expired CO2
concentrations and respiratory
flow were measured and fed back
to an online computer program to
establish the position within the
ventilatory cycle and to display
this and the end-tidal CO2.
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Data analysis
The degree of oscillation of the measured respiratory
variables (a marker of the severity of the simulated PB)
was measured using the coefﬁcient of variation
(SD/mean). This has the advantage of being
dimensionless.
Statistical analysis
Continuous values are expressed as the mean±SD.
Paired t tests were performed to compare the effect of
baseline alternations with the subsequent administration
strategies within individuals. A value of p<0.05 was con-
sidered statistically signiﬁcant.
RESULTS
Cardiac pacemaker modulation as a model of periodic
breathing
Heart rate was alternated on average by 59.5±10.2 to
79.1± 10.7 bpm. AV delay was alternated in all the
patients with HF and four of the patients without HF by
a mean of 108±55 ms. Three of the four patients with
biventricular pacemakers were also simultaneously alter-
nated between biventricular pacing and right ventricular
pacing. The resting cardiac output measured on the
Finapres device was 6.9±3.6 L/min. During alternations
between the two cardiac output states, the lower cardiac
output state averaged 6.6 ±3.6 l/min and upper averaged
7.3 ±4.1 l/min. The amplitude of ﬂuctuation (deﬁned as
half the difference between upper and lower) was 2.46
±2.24 L/min representing a change in cardiac output of
3.6–30% from baseline.
Following the pacemaker-induced cardiac output
increase, the sequence of events was ﬁrst an elevation in
cardiac output, followed by a rise in end-tidal CO2 and
then by a rise in ventilation (ﬁgure 4).
Alternation of cardiac output signiﬁcantly increased the
degree of oscillation in end-tidal CO2 by 182% compared
to baseline (SD/mean end-tidal CO2 from 0.02±0.01 to
0.06±0.01, p<0.0001). This translated to a 90% increase in
Figure 3 Upper left panel is the ventilation trace of a patient with spontaneous periodic breathing who has large ventilatory
oscillations. Part of the trace (in red) has been translated to the middle left plot to demonstrate what would be seen in the lab in
real time, where it progresses in a clockwise direction. This portion of the cycle starts in mid-cycle (at 3 o’clock). Ventilation then
falls to its trough at 6 o’clock and then rises again to peak ventilation. As this second oscillation in the group of three is of lower
amplitude than the preceding peak (blue in the top left panel) this part of the trace ends at mid-cycle closer to the centre of the
circle than where it started. The bottom left hand panel shows how the treatment algorithm at peak dose would be applied.
The patient would receive a high peak dose and a long duration of therapy (dark grey). The middle panel depicts moderate
oscillations, from a different patient with spontaneous PB, with the red portion starting just before trough ventilation and
continuing until just after the peak of ventilation (middle plot). This patient would receive the middle grey treatment algorithm
(bottom, middle plot). The right hand panel is that of stable breathing in which no therapy would be given by the algorithm. In this
case the cursor on screen would trace a path close to the centre.
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Figure 4 Left: Alternations in cardiac output (black) in one typical patient, every 60 s for three cycles, are followed by
oscillations in end-tidal CO2 (blue) and ventilation (red), when no dynamic CO2 is applied. Right: Oscillations in end-tidal CO2
(blue) and ventilation (red), in the same patient, are attenuated when dynamic CO2 is delivered where the troughs in end-tidal
CO2 are predicted (around peak ventilation). The motor valve position profile (green), which is proportional to the dose of CO2
delivered, varies in size and shape dependent on the amplitude and phase of the current ventilatory signal in real time. While
ventilation is still oscillatory, the amplitude of the oscillations are diminished.
Figure 5 The amplitude of oscillation of end-tidal CO2 correlates to the amplitude of oscillation of cardiac output for both
patients with heart failure (no fill) and subjects with normal systolic function (solid black fill). The amplitude of ventilatory
oscillation is closely correlated to the amplitude of oscillation of end-tidal CO2 with the regression line for heart failure patients in
grey interrupted and for non-heart failure patients in black interrupted. Typically, for any given change in end-tidal CO2 there was
a greater change in ventilation in the heart failure patients than the non-heart failure patients.
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the degree of ventilatory oscillation (SD/mean from 0.10
±0.03 to 0.19±0.09, p=0.002; ﬁgure 5). The resultant oscil-
lations in end-tidal CO2 and ventilation were highly sinus-
oidal (ﬁt-to-sine wave had r2=0.95, p<0.001 and r2=0.88,
p<0.001 respectively, ﬁgures 4 and 6).
The amplitude of cardiac output change generated in
patients without HF was greater than that generated by
those with HF (3.68±2.58 L/min vs 1.23±0.86 L/min,
p=0.05) and as a result the change in the end-tidal CO2
oscillations induced by the PPM was higher in the
patients without HF (ΔSD/mean =0.04±0.01 vs 0.03
±0.01, p=0.02). However, there was no difference in the
degree of ventilatory oscillation induced in patients with
and without HF (ΔSD/Mean=0.08±0.05 vs 0.10±0.10,
p=0.73). This may be explained by the trend towards the
ratio between the rise in ventilation and that in end-tidal
CO2 (a form of chemoreﬂex gain assessment), being
higher in the patients with HF than without (608.4
±233.5 vs 385.9±118.7 L/min/kPa, p=0.06, ﬁgure 5).
Similarly, there was a non-signiﬁcant trend towards the
time taken between the peak in end-tidal CO2 and the
peak ventilation (a measure of chemoreﬂex delay),
being longer for patients with HF than in without (22.4
±3.1 vs 16.9±6.6 s, p=0.09).
Dynamic CO2 delivery coincident with peak ventilation
In order for the supplemental inspired CO2 to arrive at
the alveolar level coincident with the peak of ventilation,
the motor had to begin its movement substantially in
advance of the peak of ventilation. The algorithm did
not require sensing of any particular level of ventilation
but rather was able to project into the future the curve
of oscillation of ventilation. What was programmed into
the algorithm was the time within the PB cycle at which
the valve should have the greatest aperture. The average
delay between CO2 being delivered and the inspired
CO2 rising was 8.8±2.5 s. With dynamic CO2 administra-
tion that was timed to be coincident with peak ventila-
tion, the size of the variation in end-tidal CO2 fell from
the untreated level of 0.06±0.01 to 0.04±0.01, p=0.001,
which is 57% of the way to the value in baseline non-
modulated breathing of 0.02±0.01. Dynamic CO2
achieved a 56% reduction in the variability of ventilation
from the experimentally induced oscillations from 0.19
±0.09 to 0.14±0.06, p=0.001, where baseline breathing
alone had oscillations of 0.10±0.03 (ﬁgures 4, 6 and 7).
There was a trend towards increased mean end-tidal
CO2 following application of the dynamic CO2 (4.91±
0.45 vs 4.84±0.47 kPa, p=0.08) and mean ventilation
compared to the pacemaker-induced PB (8.4±1.2 vs 7.8
±1.2 L/min, p=0.17; ﬁgures 4, 7 and 8).
Dynamic CO2 delivery to coincide with trough ventilation
In contrast, delivering dynamic CO2 therapy just before
trough ventilation (ie, at the opposite phase to that
which is predicted to be helpful) failed to attenuate
Figure 6 Raw data from one individual where each 60 s cycle has been time aligned. The far left hand panel is 240 s of
baseline ventilation where no intervention has taken place. The middle panel is the data from cardiac output oscillations alone
every thirty seconds resulting in oscillations in the respiratory gases and ventilation. The right hand panel shows five time-aligned
cycles where dynamic CO2 therapy was applied coincident with peak ventilation while 60 s cardiac output alternation continued
and the resultant amplitude of end-tidal CO2 and ventilatory oscillations were attenuated.
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both the degree of oscillation of end-tidal CO2 (0.06
±0.02 at antiphase vs 0.06±0.01, untreated, p=0.75) or
ventilation (0.024±0.09 at antiphase vs 0.19±0.09
untreated, p=0.17, ﬁgure 7, table 2).
DISCUSSION
This study demonstrates that it is possible to produce a
human model of PB using cardiac pacemaker manipula-
tion both in patients with preserved systolic function and
in patients with HF (ﬁgures 4, 5 and 6). The enhanced
chemoreﬂex gain that is seen in patients with HF
increases the ability of manipulations of cardiac output
to affect ventilation. We were able to apply this model of
PB to develop a potential therapeutic approach; to
deliver small, graded amounts of CO2 carefully timed
within the PB cycle.12 This improved stability and mini-
mised the increment in end-tidal levels of CO2 and
mean ventilation whose adverse effects might have pre-
vented a simpler static CO2 regime from being adopted
as a therapy.
A dynamic solution for a dynamic problem?
Ventilation is tightly controlled by negative feedback
whereby a rise in arterial CO2 elicits the reﬂex physio-
logical response of increased ventilation which tends to
reduce arterial CO2. In conditions such as PB where this
chemoreﬂex is exaggerated and delayed,24 this reﬂex
response actually generates oscillations in end-tidal CO2
and ventilation.25
Previously, low arterial CO2 concentrations seen in PB
and HF have been targeted using static CO2 (either by
continuous supplementary CO2 or by adding dead-
space). While often successful in stabilising ventilation,
this is at the clinically prohibitive cost of increased mean
ventilation.12
In the present study, we tested a dynamic administra-
tion algorithm. Rather than delivering CO2 statically, this
gave small ﬁnely adjusted concentrations of CO2 for
small parts of the PB cycle aiming to speciﬁcally ﬁll in
the troughs of CO2 produced by hyperventilation rather
than to raise the overall CO2 level.
12
Figure 7 By alternating cardiac output via pacemakers
labelled ‘Untreated’, there was a 182% increase in end-tidal
CO2 oscillations compared to stable breathing without
intervention labelled ‘Baseline’. When dynamic CO2 was
applied to the experimentally induced oscillations coincident
with peak ventilation, this abolished 57% of the induced
oscillations. When dynamic CO2 was applied 180° after peak
ventilation there was no significant difference to
pacemaker-induced oscillations alone. Degree of ventilatory
oscillation during stable breathing ‘Baseline’, with alternation
of cardiac output using pacemakers ‘Untreated’, when
dynamic CO2 is applied at peak ventilation and following
application of dynamic CO2 coincident with trough ventilation.
Figure 8 Dynamic CO2 administration, which successfully
attenuated 57% of the induced oscillations in end-tidal CO2,
was not associated overall with a significant increase in mean
ventilation compared with untreated experimentally induced
pacemaker oscillations alone.
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Why do we need a pacemaker model of periodic
breathing?
In clinical practice, PB and central sleep apnoea typic-
ally appear and disappear unpredictably during a
recording,15 26 27 presenting a problem while developing
interventions where numerous aspects of the algorithm
could, in principle, be adjusted. For example, in
dynamic therapy, the timing of CO2 delivery is likely to
be important, and a large number of variants of timing
are possible.12 If each conceivable variant of timing had
to undergo a whole night of testing in numerous
patients, it would take an impractically long time to
make progress. Likewise, the maximal concentration of
CO2 and the proﬁle of administration within the PB
cycle are further aspects of the therapeutic algorithm
that require investigation. If a grid of combinations of
even these three aspects were to be tested, it would be
even more impractical.
The purpose of our experimentally inducible PB is to
allow ventilatory oscillations to be generated at will in
patients, with a predictable and consistent pattern.13 14
Pre-emptive predictive CO2 delivery: from theory to
practice
The ﬁndings of this study are consistent with other ﬁnd-
ings by our group that dynamic CO2 therapy may stabil-
ise ventilatory oscillations, but only if the timing and
dose used are correct.12 16 These studies identiﬁed that
if dynamic CO2 was correctly timed to be coincident
with peak ventilation, it had the potential to signiﬁcantly
attenuate the oscillations, but if CO2 delivery was incor-
rectly timed (arriving during the hypoventilation phase),
it could even make breathing more unstable.12 16
Potential clinical impact
Static CO2 is not clinically utilised due to the undesir-
able consequences of large doses of CO2.
28 Dynamic
CO2 therapy achieved signiﬁcant amelioration of the
induced PB but without increasing mean ventilation
(ﬁgure 8). This is consistent with the work by our group,
which suggests that dynamic CO2 administration can sta-
bilise oscillatory ventilation without the cost of a statistic-
ally signiﬁcant increase in mean ventilation. It is likely
that there was in fact a small increment in this study, as
some supplemental inspired CO2 was given. If we had
used higher concentrations, the effect on CO2 and venti-
lation would have been proportionately larger. However,
it is unlikely that administered over a short part of the
PB cycle and in varying concentrations, it would amount
to delivering the same amount of CO2 as is delivered
with static CO2 therapy. The effect of static CO2 therapy
on ventilation is not often explicitly stated but can be
calculated from the equation below:
DV ¼ VCO2
DðFetCO2  FiCO2Þ
where DV is the change in alveolar ventilation, Vco2 a
constant volume of body production of CO2,
D(FetCO2−FiCO2) is the change in difference of end-
tidal CO2 to inspired CO2.
This equation can also be used to calculate the rise in
mean ventilation that occurred in the previous pub-
lished clinical studies using both static CO2 delivery and
the addition of even very small amounts of dead space,
which increased ventilation ranges from 24% to 96%.12
This degree of increase in ventilation imposes large
increments in the patients’ metabolic requirements,
which may be particularly precariously balanced in HF,
in addition to the CO2-induced potentiation of the sym-
pathetic nervous system and sleep disruption.24 However,
the increment with dynamic CO2 is likely much smaller
than this, by virtue of the fact that the overall dose of
CO2 administered is so very much smaller. It is not
known whether the efﬁcacy of dynamic CO2 on attenuat-
ing ventilatory oscillations would be greater in spontan-
eous PB than it is in driven PB. In spontaneous PB each
cycle of PB is the driver for the next. If the therapy
attenuates one cycle, then this action may have an
Table 2 Results of dynamic CO2 administration on end-tidal CO2 and ventilation
Mean (kPa) SD/mean Mean (L/min) SD/mean
Baseline 4.83±0.58 0.02±0.01 7.8±1.8 0.10±0.03
Untreated 4.84±0.47 0.06±0.01 7.8±1.2 0.19±0.09
p vs baseline 0.90 <0.001 0.6 <0.01
Predicted optimum 4.90±0.45 0.04±0.01 8.4±1.2 0.14±0.06
p vs baseline 0.40 <0.001 0.5 <0.01
p vs untreated 0.1 <0.001 0.2 <0.01
Antiphase to predicted optimum 4.85±0.43 0.06±0.02 7.2±1.8 0.24±0.09
p vs baseline 0.5 0.001 0.2 <0.001
p vs untreated 0.2 0.8 0.30 0.2
p vs optimal 0.2 0 0.1 <0.01
Degree of oscillation and mean end-tidal CO2 and ventilation when the patients were quietly observed at rest ‘Baseline’, cardiac output was
alternated using a pacemaker to induce oscillations ‘Untreated’, dynamic CO2 was applied to the induced oscillations coincident with peak
ventilation ‘Predicted Optimal’, and dynamic CO2 was applied to the induced oscillations coincident with trough ventilation ‘Antiphase to
predicted optimum’.
Baruah R, Giannoni A, Willson K, et al. Open Heart 2014;1:e000055. doi:10.1136/openhrt-2014-000055 9
Heart failure and cardiomyopathies
group.bmj.com on June 14, 2016 - Published by http://openheart.bmj.com/Downloaded from 
indirect effect of attenuating the second cycle, separate
from the direct therapeutic effect on the second cycle.
Another advantage of a dynamic therapeutic approach
to a physiological problem such as PB is that it would be
automatically titrated to severity such that if breathing
stabilises, therapy ceases.
This study also incidentally raises the possibility that
cardiac output modulation by a pacemaker could be
used therapeutically to counteract oscillation rather than
to induce it.
Study limitations
This study only veriﬁes that a PB pattern can be elicited
at will and that this experimentally induced PB can be
used to develop and reﬁne dynamic CO2 algorithms.
This is a proof-of-concept study and does not aim to
assess the effect of this algorithm on spontaneous PB
and, as a non-apnoeic model of PB, may not mimic true
apnoeic PB. In this study, the experimental PB was not
completely eliminated but it was attenuated by about
one half. This may be because of the limitations of
dynamic CO2 delivery in attenuating ventilatory oscilla-
tions, or it may be because the driver to physiological
oscillations (changes in cardiac output) was unremitting.
If such a technology were developed and applied to
spontaneous PB, the degree of efﬁcacy might be more
or less than this, which can only be found from future
randomised prospective trials. In addition, it is possible
that even the level of decrease seen here may be sufﬁ-
cient to break the vicious circle that gives rise to PB.
This study was designed to detect mean effects across
the entire group and, therefore, any comparisons
between patients with and without HF are likely to be
underpowered. One example is that there was only a
trend towards longer chemoreﬂex delays in patients with
HF compared with without HF, whereas previous studies
have consistently reported this difference to be statistic-
ally signiﬁcant.4
A facemask and pneumotach were used to unambigu-
ously quantify the concentration of CO2 being inspired
and the end-tidal CO2. Although such masks are poorly
tolerated in normal clinical practice,29 and they necessi-
tate an element of dead space, dynamic CO2 administra-
tion need not be dependent on tightly ﬁtting masks.
This particular study did not address whether static
CO2 therapy would have been efﬁcacious in reducing
the experimentally induced oscillations, and at what cost
to mean ventilation, in this novel model of PB. Future
studies might beneﬁt from incorporation from a static
CO2 arm that is either matched to the dynamic CO2
arm, either in terms of the average amount of CO2 deliv-
ered over the cycle, or in terms of efﬁcacy on ventilatory
stability. The latter option might be complex because it
would require the dynamic therapy to always be done
ﬁrst and then a variety of static CO2 concentrations to
be tested in order for the equivalent one to be
identiﬁed.
CONCLUSION
We describe a method of inducing PB at will in subjects
with pacemakers that permits evaluation of the impact
of proposed therapies on ventilatory patterns in a con-
trolled manner. Further, we developed a real-time pre-
emptive CO2 stabilisation system that relies only on venti-
latory monitoring.12 16 Such a system allowed successful
prediction of where end-tidal CO2 was likely to fall, and
by delivering controlled doses of inhaled CO2 at this
time, it was possible to substantially attenuate both oscil-
lations in end-tidal CO2 oscillations and ventilation.
Critically, ventilatory oscillations were attenuated without
increasing either mean end-tidal CO2 or mean ventila-
tion, making pre-emptive dynamic CO2 therapy a poten-
tially attractive therapeutic intervention in conditions
such as PB in HF.
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